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PROFILE
A Conversation with John Suiston
Valerie Richardsona
Yale School ofMedicine, NewHaven, Connecticut
SirJohnSulston wasaco-winneroftheNobelPrizeforMedicinein2002. Hewontheprizeforhisdiscoveries
concerning "geneticregulationofoigandevelopmentanddprogrammedcelldeath,"alongwithhiscolleagues
SydneyBrennerandH. RobertHorvitz. LI: SulstonwasfoundingdirectoroftheSangerCentre, Cambridge,
England, wvhich heheadedfivm 1992 to 2000. From 1993 to 2000, heledtheBritish am7nofthe international
teamselectedto workontheIIuman GenomePrject. lIeisco-authorofthebookTheCommuonThread:
AStory ofScience, Politics, Ethics, andthe Human Genome,publishedbyJoseph HenryPress in 2002.
This interview was conducted on December 20, 2002, shortly after Dr Sulston was awarded his
Nobel Prize and was originally broadcast on that date on radio station WPKYM-FM in Bridgeport,
Connecticut. The interview was condtucted by ValerieRichardson, the ManagingEditorofThe Yale
Journal ofBiology and Medicine.
Dr Sulston has been an outspoken advocate against letting thedatafrom theHuman GenomneProject
becomepropertyofcommercialinterests thatwouldchargetheworldsscientificcommunityforitstuse.
Sinceleaving theSangerInstitute, hehas workedwith OxFam, theOxfordCampaignforFamineRelicef
YJBM: ItA such a pleasure to have this
opportunity tospeakwithyou. So whatwas
it likegetting the NobelPrize?
JS: Well, it was amazing. I gather that
some people expect to wintheNobelPrize,
but this was not the case for me at all. I'm
very pleased that it has come because it's
recognition for work on this little one-mil-
limeter nematode worm that Sydney
Brenner's group started studying back in
the 1960s. A lot of people worked on it,
and I feel great that I'm a representative of
that community and have brought the field
to this recognition.
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YJBM: Well whv don'tyou talkabout that
little worm. You spent a lot ofyour early
careerworkingon thegeneticstrunctureofthis
worm, C. elegans. What was sosignifcant
about it that you and your scientific col-
leagues spent so much time working on it?
JS: It filled the gap. You have the single-
celled organisms that everybody works on,
lots of bacteria and yeasts, which in fact
got last year's NobelPrize,thecell cycle in
yeast.The worm has about a thousand
cells. All living things are madeup ofcells,
and going from one cell to a thousand, as
the worm does, is a bigjump for evolution
because the cells have to sticktogether and
talk to each other and become different
from each other in order to make it work.
It's not a matter ofhaving a blob ofcells,
obviously. [The worm] isjustlikeus. There
are specialized cells making skinand mus-
cles and guts and one thing and another.
But when yougo up to the next model, the
insects, which are commonly used, they
have many manymillions ofcells. And we
haveahundredmillionmillion inourbodies.
This is rather a lot to deal with. Youcan do
different experiments at each level, but if
you want to really look at how the cells
grow and what the rules are for making
them divide or not divide, or particularly
what caused them to die at certain times,
the worm was absolutely ideal.
So I came into Sydney's group in the
1970s, and actually I was the one along
with afewcolleagues who followed thecell
lineages, that is finding out exactly how
each cell in the worm is derived from the
single cellthat is the fertilized egg, andthat
took quite a long time. As we went along
we did experiments, killing cells deliber-
ately and finding out what effect that has
on the others and in due course finding the
signals in the DNA that cause this whole
development to happen. So the field has
really workedvery well, and it has provided
clues about how some ofthese same things
happen in the human body.
The reason for the Nobel prize this
year is because the third member of the
trio, Bob Horvitz, has really driven this
along at MIT and has acquired a large part
ofthe genetic pathway, that is the series of
genes that control programmed cell death.
A number ofthese genes are found in the
human body as well. And when they go
awry they can cause some medical condi-
tions that are troubling, for example, some
sorts of neurodegenerative diseases are
caused by these cell death pathways being
invokedinappropriately. Soyouseebylearn-
ingaboutthe genes inthe worm, we'renow
movingthat intoapplications andeventually
medical cures in the human we hope.
YJBM: And so in scientific terms was it
justa smallstepfrom workingon the worm
and its genetic structure to the human?
JS: I was was working on the cells ofthe
worm in the 1970s, and I wasn't terribly
concemed with the genes. When I finished
the celllineages, it wasalittlebitofaresting
moment for me; I wasn't sure what to do.
What I noticed wasthat lots ofpeople were
finding genes inthe sense offinding defec-
tive worms; theyknewthere was something
wrong, and they had to pin it down. It was
averytedious step to actually find the par-
ticularbit ofall the DNA. The worm DNA
has 100 millionbases, orletters, in its length
so it's really a needle in a haystackjob to
find a few thousand letters that are respon-
sible forthe gene ofinterest and thentopin
down exactly what's gone wrong. It seemed
to methatwhat one should do is to workon
the whole DNAandreallyget itmapped out
and organized as a way to make it much
easierforpeople. Westarteddoingthis inthe
early 1980s.
Andthis really was the beginning, our
efforts andothers'parallel efforts, which led
to this new field of genomics, which has
made such a difference inbiology. It's really
opened things up because now people can
go directly from the DNA. So we worked
first ofall on the worm DNA, this was inRichardson:A conversation with John Sulston 301
partnership with Bob Waterston from St.
Louis, Missouri, and when ourtwo labs had
gotten quite a long way on the worm DNA
and had gotten a lot ofthe sequencing out,
we found ourselves drawn into the much
biggerenterprise ofthe human genome. So
that's how it started. It was quite a logical
progression but the impetus the under-
standing that we needed to do this came
from our experiences withthe worm in the
beginning.
YJBM: Thieres afascinating photograph
in your book that shows you at a confer-
ence at Cold Spring Harbor standing in
front the actual model ofthe worm DNA
sequencing.
JS: Ohyes,those long, tattypieces ofpaper
spread out across the wall at the back of
the room. What itwas is thatwas calledthe
map. That was not the sequence, not the
100 million letters, but that was an assem-
bly ofabout 20,000 segments ofthe DNA,
we split it up into segments. We figured out
how they overlapped. That was the begin-
ning of the utility of it. The point ofthat
was that we stored all ofthese segments;
theyweregrowing inbacteria inourlaband
we could store them away in our freezer
and when somebody wanted a particular
segment, we wouldjust send it outtothem.
The interesting thing is we stored all of
those segments or clones away in the
beginningofthe 1980s andthey're stillbeing
sent out every week, inincreasing numbers,
actually, they're still useful. And so even
though we now have the whole sequence,
we know where the letters are, and people
still find these segments useful. They can
actually use them. They can manipulate
them and injectthem into worms and work
on the genes that way. It's curious, I never
would have imagined that something I did
would have lasted for so long.




JS: It began in the United States, and it
arose inpart fromourefforts withthe worm.
There were several key meetings that were
held inthe U.S. The first ofthese was orga-
nized by [Robert] Sinsheimer at Santa
Cruz. It was Charles De Lisi at DOE
(Department ofEnergy)b who really set it
offand announcedthat DOE wouldmake a
serious effort towards doingasimilarjob for
the humangenome culminating insequenc-
ing it. Then towards the end ofthe 1980s,
theNIH (National Institutes ofHealth) had
come firmly into hepicture, andJimWatson
was appointed to head it up.
The thing formally came into being in
1990 withaviewto decipheringthe human
genome in not more than 15 years, though
I think everybody hoped it would go a bit
faster. In fact, the worm was very much
caught up in this project because the idea
was to sequence the code of not only the
humangenome but anumberofthese other
organisms. It was very obvious that this
would help not only in developingtechnol-
ogybut inunderstanding, becauseyoucould
do experiments onthem. So that's how the
human genome project came into being.
The other thing was that Jim Watson felt it
should very much be international. The
human genome is something that is shared
by all of humankind, and so it seemed
absolutely right and natural that it should
be done in some sort ofcommunal way.
YJBM: So how long did you think this
project would take whenyou started it?
JS: Well one doesn't know. It was pretty
obvious to Bob Waterstonand me byabout
1993 that it was going to be doable. We
begantoshoutforacceleration oftheprogram
by about that time because we thought that
the machines were there and getting better
all the time, andwe were getting better; we
were automating and generally speeding
up. It no longerseemed to be like the 3,000302 Richardson:A conversation with John Sulston
million [letters], because that's the size of
the human genome, 30 timesthe size ofthe
nematode. We just knew by then that we
could do the nematode, and it was obvious
that we could scale up and do the human.
It became clear that we could do it within
the 15-year envelope.
YJBM: This book and your story is as
much about personalities as it is about
nucleotides. A person who came into the
story in the latteryears oftheproject was a
gentleman named Craig Ventet; the Direc-
tor ofCelera, a commercial biotech com-
pany. Whydon 'tyou talkabout the ongoing
debate about the genome project being a
publicly available project versus its being
a commercial venture.
JS: It does come out to personalities,
although that's partlythe way we deal with
things in our society. I've had to learn to
cope with it. It'sthe same withallthese dis-
putes with presidents and everything, you
always focus it into one person. In fact I
think it's more correct to say that it's a
political dispute really, andyou've got cer-
tain front people who do most ofthe talk-
ing. And the political dispute was quite
simply over whetherthis particularproject
should or could appropriately be done in a
for-profit way. What Celeraproposedto do
was to sequence the human genome and
keep the data in adatabaseand chargepeo-
ple for access. And after all this is some-
thingthat is commonly done, one sells goods
and services, why not?
The position of the consortium that
formed the human genome project was that
itshouldbereleased freely. Therearecertain
things we accept in our society as being
infrastructure that we do not charge for.
We don't charge each other for the air we
breathe, although we may charge for the
delivery ofair or water, but we don't think
these things should be owned at source.
We thinkthat these are common goods and
human rights. Wepossiblyfeel more strongly
about some things here in Europe. Land
for example, especially in Scandinavia, is
considered a common good where you can
roam freely. It's this kind ofdispute.
I feel that the human genome is so
basic and so common to us all. It's not
something that anybody has invented. We
all have our individual variations ofcourse,
but the background reference sequence is
common to all ofus. So it seemed to me
and to my colleagues self-evident that this
was the right way to go. It has some very
practical consequences as well.
One thing, inparticular, that affects all
scientists is that ifyou lock things up in a
private database in the fashion that was
proposed by Celera for the human genome
then some individuals who don't have
money can't get access, which is bad. And
apart from that you forbid people to talkto
each other about it because they must be
forbidden to redistribute the information.
On the other hand, when you want to deal
with these 3,000 million letters, it's not so
easy to actually do any research on it. This
is the science that we call bioinformatics,
the computing associated with the under-
standing ofthe genome. It's not so easy to
do the computing and to disseminate the
results by speaking or publication without
actuallydisseminatingthe sequence as well.
And so it's extremely inefficient and in-
hibitory to research to have a very large
body ofbasic information like the human
genome locked up in a private database.
And so I think that on that principle
alone it really was important, and it's very
good that we got it out into the public, and
the battle is over now; it's not a problem
anymore. That's the reason I think that we
should make sure this communal data is
available.
Something that increasingly concerns
me, andthe human genome isjustan exam-
ple, is that when we do privatize goods in
this way we also block them out from the
greater number ofpeople in the world who
are too poor to participate, and so I think
we have to be verycareful about ouruse of
private resources. I think it's reasonable toRichardson:A conversation with John Sulston 303
own inventions, but I don't think it's rea-
sonable to ownabasic discoverythat every-
body needs like this one.
YJBM: There was an article in The
Guardian newspaper on October 9 [2002]
alongthissametopic titled, "PatentJustice:
SirJohn'sBest WorkMayBe Yet to Come, "
talking about this issue of having this
knowledgepublicly available. Andyou've
workedwith Oxfam on this issuetoo, righl?
JS: Yes, and I've found them very good.
It'sbeen quite an eye-openerformebecause
one thinks of OxFam (the Oxford Cam-
paign for Famine Relief) as being some-
thing that collects money in tins and goes
and drills artesian wells andgenerallygoes
to help people a bit. But I think that what
is true of OxFam and a number of these
othernon-governmental organizations, such
as Medecins Sans Frontieres (MSF), for
example, that it's no goodjust doing only
that but that the reason for large numbers
ofpeople in the world being impoverished
is not rnningworldtradecorrectlyandthat
we're running it in such a way which is
increasing the wealth disparity rather than
narrowing it, and so they've realized that
it's right that they should take an active
role in arguing about exactly how interna-
tional trade relations should be conducted.
I came in at the moment when people
were started to get agitated about the so-
calledTRIPPSAgreement,theTrade-Related
Intellectual Property Rights Agreement,
which was set up by the world trade orga-
nization back in 1995, but is now begin-
ning to be implemented because there was
a delay after the initial agreement. What
we've all started to realize is that the
TRIPPSAgreement isgoingtomake impov-
erished countries even more impoverished
because it's imposing Western, that is to
sayAmerican and European, patent law on
countries who are going to get no benefit
from it whatever. It's actually going to
increase our wealth at their expense.
This seems to meto be to be absolutely
wrong, and I think OxFam is absolutely
right. I've been extremely impressed with
their researchers, andthe same is true with
MSF. These people are playing an invalu-
able role inuncovering the practicalities as
wellasthe rights andwrongs ofworldtrade
ina waythat is independent ofgovernment
and ofcorporate power. This is an unbiased
view, I think I've learned a lot from them,
and I intend to go on doing so.
YJBM: So this is ongoing workforyou?
JS: It's sort ofnotorious that Nobel Prize
winners start to spout offabout all sorts of
things theyknowabsolutely nothingabout.
My one excuse is that I've been doing this
for years now [laughs]. One has to accept
that the Nobel gives you a bit ofa higher
platform, so you have to be careful what
you saybecause people are liable to listen.
So I shall go on learning. This is what
excites me at the moment to learn more
about this and see ifI can't push this a lit-
tleto swingthings backmore where Ithinik
they ought to be.
YJBM: Thisissuchafascinatingtopic, and
the medicalandclinicalapplicationsfrom
this work arejust so huge. And I would
guess thatyou, thepeoplewhoarework-ing
on theseprojects, are so much at the very
beginning. The genome has been mapped
at this point, you know where the letters
are, but the nextpart is to go in andfigure
out whateverything does.
JS: Absolutely. It's trivial what's beendone
so far compared to what is to come. That
goes back to my point about the database
and why it's got to be made freely avail-
able. It gets assimilated into biology now,
andpeople can access it without wondering
whether they can afford to access it. It's
just there, and people can dip in and dip
out and contribute. It's a huge resource.
People sometimes ask, "What's coming
out of the genome?" and it's really the304 Richardson:A conversation with John Sulston
wrong question to ask It's like saying,
"What's coming out of biology?" That's
the way I see it going forward. And it is
very exciting because I think we're now
enhancing the efforts of biologists by
bringing in this information from the
groundup. Not onlythe humangenome but
lot's ofgenomes that have been sequenced
and are now publicly available.
YJBM: What is itabout this wholeproject
andabout understanding thehuman in this
way that frightens so many people? A
CNN/Time magazinepoll taken twoyeacrs
ago showed that 46percent ofthe respon-
dents expected harmful results from the
endeavor Fortypercent expected benefits,
but 41 percent said that the project is
morally wrong. And we've heard recent
rumors about an Italian doctor who has
supposedly clonedan embryo who is to be
born sometime nextyear
JS: I'mprettycertainthatwouldbemorally
wrong if it's true, but I'm pretty certain
that this story isn't correct. But ifit is cor-
rect, then it would be extremely danger-
ous. We know from animal cloning that
most ofthe animals die or are born defec-
tive in some way. The idea of producing
humans this way in the current state of
human development would be criminal. I
hope it isn't true although this certainly
might be done in the future. But except for
the cases of certain types of infertility, I
don't think there's any point in cloning
humans. It's far better to produce new
humans with the random recombination.
We've got so many possibilities for our
genes, and on the whole it's more fun for
the parents to produce a new kid rather
than something that's absolutely identical
to one or the other ofthem.
In general, I tend to relate the unease
to the beliefby some people that scientists
have agendas. Again I would relate it back
to the excessive use of the profit motive.
When you finance research with venture
capital, the person who has put the money
innaturally wants to get areturnas soon as
possible. So there's tremendous pressureto
move forward, to present things in the best
possible light. There was a survey, from
Duke [University], in arecent issue ofThe
NewEnglandJournalofMedicine. It stated
that, in many cases, contracts between uni-
versities and companies had caused results
notto be reported fully. So ifuncomfortable
resultsemergedduringthecourseofaninves-
tigation, researchers were being encour-
aged not to publish them, or even stopped.
Under these circumstances, it's no
surprise that people are uneasy because
theyfeelthey're notbeingtoldthe full story
all ofthe time. I think it's extremely impor-
tant interms ofthese leading edge kinds of
things that really are affecting people's
health and welfare that we have indepen-
dent experts who report in awaythat doesn't
have any kind ofagenda. We're trying that
in this country. I sit on something called
"The Human Genetics Commission,"
which is free ofanycontrols. We don't have
that bias in any way, and we're free to
investigate. And I think we need to have
plenty ofthese sorts ofpeople around who
can exercise independent judgements in
order to make the system work.
YJBM: During the acceleratedprocess of
understandingthehumangenome, whathave
been thesigniflcantdiscoveries aboutgenes
or specific parts of the genetic structure
thathaveyieldedmedical applications?
JS: You have to look at it in a series of
stages. Thethingthathas immediately come
out is greatly improved diagnostics, and I
thinkthat's the thing that people are greatly
interested in at the moment. So for all the
hereditary diseases you can understand the
variants because you have the tool of the
whole genome there as areference genome
or normal genome, so you know exactly
what you're looking at rather than having
these very prolonged and expensive map-
ping operations to find exactly where the
gene is. For cystic fibrosis, I think FrancisRichardson:A conversation with John Sulston 305
Collins estimated that it cost between 50
and 100 million dollars just to locate that
particular gene. So we don't have that any-
more; we've got the whole genome, and
locating the particular genes on it is a
much cheaper and faster operation.
You might also look at the way that
people's particular variations might influ-
ence the drugs they shouldtake. Forexam-
ple, some people are unusually susceptible
to general anesthesia because they have a
particulargenetic modification; sobymea-
suring these sorts of things, one can
improve treatment for patients. We don't
know exactly how far that's going to go.
Some people say that it will go very far,
and somepeople say the actual testing will
be too expensive, and it won't be used a
lot. I expect that it's going to be used a lot,
because I believe that testing is going to
become very inexpensive indeed.
Ithinkthat most people are excitedby
the possibilities of getting cures. People
talk a lot about gene therapy, for example,
which is quite a long way down the line.
That's the process of delivering working
genes topeople who forhereditary orother
reasons have a gene that's not working
properly. And that's really hard because
you have to deliver it and get the gene
working in the right place.
One sort ofcure that Ithinkisgoing to
be enhanced inshort order(by short I mean
a decade or two) is cancer treatment. The
reason for that is that we can investigate
and find exactly what the changes are in
particular tumor types that cause them to
continue growing uncontrollably, eventu-
ally killing the patient. By having those
targets, one will first ofall be able to diag-
nose accurately, but in this case one will
probably be able to move to cure because
you're trying to get something to kill the
tumor rather than bring in a healthy gene.
That's a relatively easy matter, and I think
that delivery methods will be brought in
within the next decade or so. So I think we
are going to see big changes in cancer
treatment as a result. Beyond all of that,
everything, all ofmedicine is affected, and
people are going to be ingenious in using
this new information invarious ways.
YJBM: SoIguess thatgoesalongwith the
question with which Iwanttofinish, which
is one you pose yourself in the book,
"Where does all of this achievement-
draft andfinished - stand in the overall
scheme ofthings? Is it a BIGIDEA orjust
an episode?"
JS: What I want to say there is that we are
in the middle ofa really big era ofchange
of understanding, which I would roughly
define as molecular biology, in the sense
that it subsumes most ofbiology in some
sense. This is true notjust for humans, of
course, but for plant scientists and every-
body. It is quite incredible to be dealing
with the molecules of life. And it began
around the time that DNA was discovered
50 years ago. What we say in the book is
that the sequencing ofthe human genome
is asplendidthingbecause it's sort ofobvi-
ously iconic for us to have our own code.
Youcan walkaround with it onaCD ifyou
want [laughs] andsay,"Hereweare,here're
the instructions formakingahumanbeing."
YJBM: We could get into some privacy
issue here too.
JS: Yes, that's right. But it's not meaning-
ful except in terms of the understanding
what'sgoing to come, and so people should
feel that it's really an exciting thing. It's
likeunwrapping aChristmas present that is
akit,andyouhaveto figureouthowtobuild
the kit.
YJBM: So you've retired as the head of
the Sanger (entre. What isyour scientific
research these days?
JS: All the way along, I've been working
onthenematode, andwe're stillworking on
tidying up little bits of its genome. I've
also been spending lots oftime writingthis306 Richardson:A conversation with John Sulston
book and with the things rising out ofthe
book. After what to me was the quite
shocking episode of the attempt to priva-
tize the human genome, I've become quite
politicized and become quite concerned
with the quite broader aspects that we've
been discussing right now. I don't know
exactly where it's going to go. I don't ask
where I'm going, I just like to move for-
ward to whatever interests me at the time.
To be honest, this business ofsetting world
trade to rights is most important. If I can
help OxFam and any of the others in any
way to do that, then I would be more than
delighted.